fig7

Figure 7. Ferroptosis resistance induced by alterations in iron metabolism. The upregulation of ferroportin, TRPML1, PROM2, and ferritin, or downregulation of TFRC, decreases intracellular free iron levels, leading to ferroptosis resistance in cancer cells. In addition, activation of RBCK1 and SOX13 may promote ferroptosis resistance by decreasing iron-mediated mitochondrial ROS. Ferlixit, an activator of ferritinophagy; BIRB and SB202190, P38 inhibitors; KRIBB11, a HSF1 inhibitor. TRPML1: Transient receptor potential mucolipin 1; PROM2: prominin 2; RBCK1: RANBP2-type and C3HC4-type zinc finger containing 1; SOX13: SRY-box transcription factor 13; HSF1: heat shock transcription factor 1; ATF1: activating transcription factor 1; TFRC: transferrin receptor; RBFOX2: RNA binding fox-1 homolog 2; METTL16: methyltransferase methyltransferase-like protein 16; SENP3: SUMO specific peptidase 3; DUSP4: dual-specificity phosphatase 4; YTHDC1: YTH N6-methyladenosine RNA binding protein C1; LTF: lactotransferrin; MFN2: mitofusin 2; SCAF1: SR-related CTD associated factor 1.